A
AVEO Oncology
Biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics
About AVEO Oncology
AVEO Oncology, now part of LG Chem, operates as a commercial-stage biopharmaceutical firm with a sharp focus on the oncology sector. The company's primary objective is the development and commercialization of therapeutics aimed at improving outcomes for cancer patients. AVEO's history dates back to its founding in 2001, initially incorporated as GenPath Pharmaceuticals, Inc., before rebranding to AVEO Pharmaceuticals, Inc. in 2005. The company was established by a team of scientists with distinguished backgrounds: Ronald A. DePinho, whose work has been pivotal in cancer research and aging; Lynda Chin, a respected cancer genomicist; and Kenneth E. Weg, who brought extensive biopharmaceutical leadership experience to the venture. A significant milestone in the company's journey was its acquisition by LG Chem in January 2023 for $571 million in an all-cash transaction, positioning AVEO as the U.S. commercial hub for LG Chem's Life Sciences division's oncology efforts.
The core of AVEO's commercial activity is FOTIVDA® (tivozanib), an oral, next-generation vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI). The U.S. Food and Drug Administration (FDA) approved FOTIVDA in March 2021 for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) who have undergone two or more prior systemic therapies. This approval was a landmark achievement, providing a new treatment option for a patient population with a significant unmet need. FOTIVDA's mechanism of action is designed to be highly potent and selective, which helps in blocking the growth of blood vessels that tumors need to survive and spread, while potentially minimizing off-target side effects. The company's revenue stream is primarily derived from the sales of FOTIVDA® in the United States.
Beyond its current commercial focus, AVEO maintains a pipeline of other investigational programs in various stages of clinical development. The company is actively exploring the potential of tivozanib in combination with other immuno-oncology therapies to address different stages of RCC and other types of cancer. This strategy of expanding the applications for its lead product while advancing other pipeline candidates demonstrates a commitment to long-term growth within the competitive oncology market. The company targets oncologists and healthcare providers within specialized cancer treatment centers as its primary client base.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2001
- Headquarters
- Cambridge, United States
- Listing
- IPO 2010
- Employees
- 202
- Open positions
- 8
- Dealroom signal
- 73.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Oct 2022 | $566M | $566M | LG Chem | ↗ |
| POST IPO EQUITYOther financing | Mar 2021 | $48M | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth |
|---|---|---|
| 2026 | $42M | 0% |
| 2025 | $42M | 0% |
| 2024 | $42M | 0% |
| 2023 | $42M | 0% |
| 2022 | $42M | 0% |
| 2021 | $42M | +605% |
| 2020 | $6M | — |
Growth signals
Latest recorded traffic for AVEO Oncology is 7.1K monthly website visits, up 69% over the last three months. AVEO Oncology's team grew 2% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
AVEO Oncology in the Cambridge ecosystem
The AVEO Oncology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Series B and later4 investors entered at this stage
Bessemer Venture Partners
Venrock
Biogen
Hercules Capital
Other known investors2 additional known investors
LG Chem
NEA
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AVEO Oncology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AVEO Oncology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










